Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

GHK (Copper-Free) Dosage Chart - Peptide Dosages

GHK (Copper-Free, 50 mg) Dosage Protocol The plain human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) supplied without pre-formed copper — sold by vendors as “GHK Basic,” a separate SKU from the blue GHK-Cu copper complex. This page documents the inject

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

GHK (Copper-Free, 50 mg) Dosage Protocol

The plain human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) supplied without pre-formed copper — sold by vendors as “GHK Basic,” a separate SKU from the blue GHK-Cu copper complex. This page documents the injectable/reconstitution format that research-peptide sellers market. Be clear up front: there is no human clinical trial of injectable GHK, and because GHK binds copper with an albumin-like affinity it converts to GHK-Cu once copper is present. Research and educational reference only; not a drug, not FDA-approved, not medical advice.

The natural human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys), supplied without a pre-formed copper ion and sold by vendors as "GHK Basic" — a separate product from the blue GHK-Cu copper complex. Because GHK binds copper with an albumin-like affinity, copper-free GHK converts to GHK-Cu once copper is available, so "copper-free" is a formulation choice rather than a distinct biology.

There is no clinical dose. Research-peptide vendors reconstitute a 50 mg vial in about 2 mL bacteriostatic water (25 mg/mL) and describe roughly 1-2 mg per day subcutaneously, cycled 4-8 weeks — figures that are community/vendor convention, not medical guidance. The main vendor source explicitly states that no human randomized trial has confirmed an optimal injectable schedule.

No human clinical trial of injectable GHK exists in any form, and copper-free GHK has no dedicated injectable study. The human efficacy that does exist is topical and cosmetic and used GHK-Cu (the copper complex); every injectable/systemic study is in animals — subcutaneous rat wound chambers, intra-articular rat injections where the benefit was transient, and intraperitoneal mouse models. Cosmetic/research compound, not FDA-approved.

Quickstart Highlights

GHK is the human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys), a three-amino-acid sequence that occurs naturally in human plasma and was first described in 1973 as an activity in human albumin that made aged tissue behave more like young tissue[1][2]. “Copper-free GHK” — marketed as GHK Basic — is simply the peptide supplied without a pre-formed copper ion, as opposed to the blue GHK-Cu complex used in most cosmetic research.

This page covers the injectable / reconstitution format some research-peptide vendors sell, and it opens with two honest limits that frame everything below. First, the chemistry: GHK binds copper (Cu²⁺) with an affinity close to the copper-transport site on albumin, so it readily picks up available copper and becomes GHK-Cu[1][2] — “copper-free” is a starting formulation, not a copper-free biology. Second, the evidence: there is no human clinical trial of injected GHK in any form, and copper-free GHK has never been studied by injection at all[3][5][7]. GHK is not a drug and not FDA-approved; this is a research reference, not a recommendation to inject anything.

Mix & measure GHK (Copper-Free) · 50 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Supplies Needed

GHK Basic is sold as a lyophilized research vial, so the generic reconstitution kit below is what vendors pair with it. Note that this is documentation of the injectable format — not an endorsement of injecting a peptide whose only human evidence is topical.

Protocol Overview

GHK is a naturally occurring human tripeptide (Gly-His-Lys), studied for decades — almost always as its copper complex GHK-Cu — for skin remodeling, wound healing and antioxidant effects[1][2]. “Copper-free GHK,” or GHK Basic, is the same peptide without a pre-formed copper ion, offered by some vendors in an injectable-style lyophilized vial.

The honest core of any overview is twofold. On chemistry: because GHK binds copper with an albumin-like affinity and readily forms GHK-Cu[1][2], the biology people attribute to “GHK” is really the biology of GHK-Cu, and the one dedicated copper-free study was in-vitro and explicitly a proxy for copper-GHK[3]. On route: the human evidence is topical/cosmetic, the injectable evidence is animal only[5][7][8], and copper-free injected GHK has no study of its own. It is not FDA-approved for anything.

Dosing Protocol

Reference reconstitution and community-dose figures only (50 mg vial in 2 mL → 25 mg/mL). The dose column reproduces the vendor convention for GHK-Cu[12]; it is not a clinically validated schedule and there is no copper-free injectable dosing literature. U-100 units assume 100 units = 1 mL.

1.0 mg — conservative[12]

0.04 mL

4 units

1.5 mg — standard[12]

0.06 mL

6 units

2.0 mg — higher[12]

0.08 mL

8 units

50 mg — whole vial

2.00 mL

200 units (≈25–50 community doses)

Why GHK (Copper-Free) draws research interest

These are the directions researchers and the peptide community most often explore GHK (Copper-Free) for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

There is no human trial of injectable GHK — in any form

This is the fact that should anchor the whole page. Targeted searches for injected or mesotherapy GHK/GHK-Cu return no controlled human trials; the injectable evidence is entirely animal — subcutaneous wound-chamber studies in rats, weekly intra-articular injections in rats (where the benefit disappeared once treatment stopped), and intraperitoneal dosing in mice. Copper-free GHK specifically has never been studied by injection at all. Anyone injecting it is copying a vendor convention, not following clinical data.

Copper-free GHK does not stay copper-free

GHK binds copper with an affinity close to the copper-transport site on human albumin, so in solution, on skin, or in the body it grabs available copper and becomes GHK-Cu. That is why researchers study GHK-Cu, why a reconstituted "copper-free" solution can develop a blue tint, and why "copper-free" is best read as a starting formulation rather than a genuinely copper-independent molecule. The one dedicated copper-free skin study was in-vitro and framed itself as a proxy "to obtain the effects of copper-GHK."

The strongest claims come from company-affiliated reviews

The sweeping statements about GHK — modulating thousands of genes, "resetting" tissue toward health, broad anti-aging actions — trace mostly to review papers by authors affiliated with a company that sells GHK-Cu cosmetics. They are reviews, not controlled trials, and they describe the copper complex used topically. Read honestly, GHK is genuinely interesting skin biology with real but modest cosmetic evidence for GHK-Cu — not a proven injectable therapeutic.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

A 50 mg vial in 2 mL bacteriostatic water is 25 mg/mL. A 1 mg amount is then 0.04 mL = 4 units on a U-100 syringe. Reconstitution math shown for transparency, not as dosing advice.

Vendor blogs suggest ~1–2 mg/day subQ, cycled 4–8 weeks[12]. This is community planning, not clinical guidance — and the source says no human RCT has set an injectable schedule.

GHK binds Cu²⁺ with near-albumin affinity and becomes GHK-Cu once copper is available[1][2]. A reconstituted “copper-free” solution can turn blue as it takes up copper.

No human trial of injectable GHK. Human data are topical/cosmetic for GHK-Cu[1]; injectable data are animal only and, where positive, transient[7]. Not FDA-approved.

Dosing & Reconstitution Guide

Copper-free GHK has no established injectable dose. The figures below are the community/vendor convention that circulates on research-peptide blogs, reproduced here for transparency and framed honestly against the fact that no human trial supports them[12]. They are not a recommendation to self-inject an unapproved copper-binding tripeptide.

Standard / Gradual Approach

The convention that vendors publish for the copper peptide (GHK-Cu) is roughly 1–2 mg per day subcutaneously — often tiered as ~1.0 mg (conservative), 1.0–1.5 mg (standard) and 1.5–2.0 mg (higher) — cycled for about 4–8 weeks[12]. There is no separate dosing literature for copper-free injectable GHK whatsoever; these numbers are borrowed from the copper complex.

The single most important caveat is the source’s own admission: the primary vendor guide states plainly that “no human RCT has confirmed an optimal injectable schedule” and that its timelines are “anchored to community planning, not RCTs”[12]. In other words, this is a planning heuristic from sellers, not a clinically validated regimen. The real human evidence for GHK is topical and cosmetic, and it used GHK-Cu[1].

Where injected GHK-Cu has been tested — in animals — the results temper rather than support enthusiasm. Weekly intra-articular GHK-Cu injections in rats produced a benefit that was transient and lost once treatment stopped, with no difference in ultimate strength or histology[7]. Subcutaneous and intraperitoneal animal work shows biological activity[5][8], but none of it establishes a human dose, and none of it used the copper-free peptide.

Reconstitution Steps

If a 50 mg vial is reconstituted, 2 mL of bacteriostatic water gives 25 mg/mL, a concentration that fits a standard 3 mL vial and makes small draws measurable. This is shown to make the arithmetic transparent; it is not an instruction to inject.

▪Sanitize: swab the vial stopper and the bacteriostatic-water stopper with fresh alcohol pads and let them air-dry.

▪Add 2 mL slowly: draw 2 mL of bacteriostatic water and let it run down the inside wall of the vial, giving 25 mg/mL.

▪Dissolve gently: let it stand about 30 seconds, then roll the vial between your palms. Do not shake. Discard if cloudy or particulate.

▪Expect a colour shift: a “copper-free” solution can turn faintly blue-purple as GHK chelates ambient copper and forms GHK-Cu[2] — chemistry, not contamination.

▪Refrigerate: store the reconstituted vial at 2–8 °C, protect it from light, and never freeze it.

Storage Instructions

Lyophilized vials are stable refrigerated and should be protected from light; follow the supplier’s handling guidance for the powder, and never freeze a vial once reconstituted.

After reconstitution with bacteriostatic water, store at 2–8 °C, protect from light, and use within roughly 28 days with aseptic technique. Because GHK is hydrolytically and oxidatively labile[9], degradation is a real concern; a deepening blue-purple colour signals copper uptake (GHK-Cu formation), while cloudiness or particulates mean it should be discarded.

Important Notes

These are the points most often dropped when copper-free GHK is marketed as an injectable “research peptide.”

▪No human injectable evidence: there is no controlled human trial of injected GHK or GHK-Cu, and copper-free GHK has no injectable study at all[3][5][7]. The dosing that circulates online is vendor convention for the copper complex, and the source itself says no RCT has set a schedule[12].

▪Copper-free GHK becomes GHK-Cu: GHK binds Cu²⁺ with an affinity close to albumin’s copper site and spontaneously forms the copper complex when copper is available[1][2]. A “copper-free” injection does not deliver a copper-free biology — it delivers a peptide that then acquires copper.

▪The real evidence is topical and for GHK-Cu: controlled human data on GHK are cosmetic, topical, and used the copper complex[1]; the collagen, GAG and gene findings are in-vitro or animal[4][6][11]. None of it validates injecting the copper-free peptide.

▪Injected animal benefits can be transient: weekly intra-articular GHK-Cu in rats improved healing early but the effect was lost after treatment stopped, with no difference in final strength[7] — a caution against assuming durable benefit from injection.

▪Delivery is genuinely hard: GHK-Cu is highly hydrophilic (logD around −2.4) with poor skin permeation and hydrolytic/oxidative lability[9][10], which is why formulation is an active research problem — and why simple claims for any route should be treated skeptically.

▪Cosmetic/research compound, not an approved drug: GHK/GHK-Cu is not FDA-approved to treat wrinkles, wounds, hair loss or anything else, and the boldest claims (genome “resetting,” broad anti-aging) rest on company-affiliated review work[2][11].

How This Works

GHK’s biology begins with copper. The tripeptide has a high affinity for Cu²⁺ — comparable to the copper-transport site on human albumin — and readily forms the GHK-Cu complex, the form studied in almost all of the research[1][2]. Copper is a cofactor for enzymes central to connective tissue, so a peptide that shuttles copper has a plausible route to influencing the extracellular matrix.

In cell and animal models, GHK-Cu stimulates collagen synthesis in fibroblasts (maximal near 10⁻⁹ M)[4], increases sulfated glycosaminoglycan synthesis[6], and — when injected into subcutaneous wound chambers in rats — produces a dose-dependent increase in collagen, protein and GAG accumulation[5]. Broader company-affiliated reviews describe GHK modulating a large number of human genes toward repair[11]. The single dedicated copper-free study found copper-free GHK raised keratinocyte proliferation and integrin/p63 expression “similar to copper-GHK” in skin-equivalent models — but it was in-vitro and explicitly a proxy “to obtain the effects of copper-GHK,” with the authors stating “further study is necessary”[3].

The honest limit is translation and route. Almost all of this is in-vitro, animal or review-level, the human cosmetic evidence is topical and used GHK-Cu[1], and where GHK-Cu has been injected in animals the benefit was activity-level and sometimes transient[7][8]. So the mechanistic story of “copper-free injectable GHK” is, in the end, the story of topical GHK-Cu — because that is what copper-free GHK becomes, and that is where the data are.

Lifestyle Factors

For skin and connective-tissue health, the interventions with the strongest evidence are unglamorous and matter far more than any peptide: daily broad-spectrum sunscreen (the best-proven anti-ageing step there is), not smoking, sleep, protein-adequate nutrition and a simple, consistent routine. These carry evidence that an unapproved injectable tripeptide does not.

The honest “daily habits” note here is a caution rather than a stack: because the only real human evidence for GHK is topical GHK-Cu[1], a well-formulated topical is the evidence-based way to use this peptide chemistry — and an injectable copper-binding tripeptide with no human data is not a substitute for medical care or for the basics above.

Potential Benefits & Side Effects

Evidence tier: no human trial of injectable GHK; human efficacy is topical/cosmetic and for GHK-Cu; injectable data are animal only. The “effects” below are what the GHK-Cu literature reports (mostly in-vitro, animal or topical-cosmetic); the “considerations” are the honest counterweight, led by the absence of any injectable human evidence.

Reported Effects

▪Skin appearance — topical, controlled, GHK-Cu: controlled studies on aged skin report improved firmness and elasticity and reduced fine lines, photodamage and hyperpigmentation with topical GHK-Cu[1].

▪Matrix synthesis — in-vitro/animal, GHK-Cu: GHK-Cu stimulates collagen[4] and glycosaminoglycan[6] synthesis, and increases connective-tissue accumulation when injected into rat wound chambers[5].

▪Gene modulation — review-level, GHK-Cu: company-affiliated reviews describe GHK-Cu up-regulating repair and antioxidant programs across many genes[11] — interesting, but review and in-vitro, not clinical proof.

▪What is not established: that injected GHK (let alone copper-free) does anything in humans. There is no human injectable trial[3][7], where injected in animals the benefit was sometimes transient[7], and GHK is not approved to treat any condition.

Common Side Effects

▪Injectable safety is essentially unstudied in humans: with no human injectable trials, there is no reliable human safety profile for injected GHK; any injection also carries the usual risks of infection, bruising and site reactions.

▪Unknown potency and identity: a grey-market “GHK Basic” vial has no verified purity or identity, and copper-binding peptides can carry variable copper loads that change their behaviour[2].

▪Stability/degradation: GHK is hydrolytically and oxidatively labile[9], so a mishandled or aged reconstituted vial may contain degradation products; discard anything cloudy or discoloured.

▪Cosmetic/research status: because GHK is not an approved drug, it should not be used to self-treat any medical condition in place of appropriate care.

Injection Technique

The workflow below documents how research-peptide vendors describe handling a reconstituted GHK Basic vial. It is educational only — there is no human clinical basis for injecting copper-free GHK, and its only human evidence is topical GHK-Cu[1].

Pre-Injection Preparation

▪Understand there is no clinical basis: injectable GHK has no human trial[3][7]; the “dose” is vendor convention borrowed from GHK-Cu[12].

▪Confirm the concentration: the reference math assumes 25 mg/mL (50 mg in 2 mL), so a 1 mg amount is about 0.04 mL — 4 units on a U-100 syringe.

▪Inspect the solution: it should be clear to faintly blue; discard it if cloudy, particulate or heavily discoloured.

Injection Procedure

▪Use a U-100 insulin syringe: a 0.3 mL / 30-unit, 29–31G insulin syringe is the format vendors describe for subcutaneous administration.

▪Subcutaneous, with site rotation: vendor convention is a small subcutaneous injection rotating sites (abdomen, outer thigh, back of the upper arm) — not intravenous.

▪Keep the volume small and measured: the community dose is ~1–2 mg (about 4–8 units at 25 mg/mL)[12]; there is no validated schedule, so do not treat these numbers as clinical targets.

Post-Injection Care

▪Store correctly: keep the reconstituted vial refrigerated at 2–8 °C, protect it from light, never freeze it, and use within about 28 days.

▪Watch for reactions: treat any injection-site reaction, rash or systemic symptom as a reason to stop and reassess, given the near-absent human safety data.

▪Keep perspective: copper-free injectable GHK is not clinically validated; the evidence-based way to use this peptide chemistry is topical GHK-Cu[1], not an unstudied injection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for GHK (Copper-Free) (50 mg Vial).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Skin & Cosmetic protocols

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Thymogen — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Thymogen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Limitations and the Human-Evidence Gap

Every honest account of NAD+ and Parkinson’s disease converges on the same conclusion: the human evidence gap is wide, and the most important results are not yet in. It is worth cataloguing the specific limitations, because they are what separate a promising research program from a proven therapy, and because they are exactly the details that hype tends to omit. The first limitation is trial size and duration. The two completed randomized trials in Parkinson’s disease enrolled 30 and 20 participants and lasted 30 days and 4 weeks respectively.1,2 These are appropriate designs for their stated purposes, safety and target engagement, but they are structurally incapable of demonstrating disease modification, which manifests as a gradual divergence of progression curves over a year or more. Any clinical improvement seen in such short trials is more likely to reflect symptomatic effects, measurement variability, or confounding than a change in the underlying neurodegenerative process. The NR-SAFE authors’ own caution about levodopa-timing confounding their UPDRS signal is a model of the appropriate humility.2 The second limitation is the responder problem. NADPARK showed that oral NR raises brain NAD+ in some participants but not others, and that clinical and metabolic signals clustered in the responder subgroup.1 This heterogeneity is scientifically important but clinically double-edged: it means that even if NAD+ elevation helps, an intention-to-treat analysis that includes non-responders may dilute the effect below detectability, while a responder-only analysis risks the statistical pitfalls of post-hoc subgrouping. Sorting out who responds, why, and how to identify them in advance is unfinished work. The third limitation is the model-to-human translation gap already discussed. The mechanistic and preclinical case is strong, but Parkinson’s disease has an unusually long history of interventions that protected neurons in animals and then failed in rigorous human trials, from antioxidants to anti-apoptotic agents to other mitochondrial strategies. NAD+ boosting could be different, but the base rate argues for caution until the phase III data are published.1,5 The fourth limitation concerns the epidemiology: the cross-sectional NHANES analysis linking higher dietary niacin intake to lower Parkinson’s prevalence is consistent with the hypothesis but cannot establish causation, and the larger EPIC-based cohort study examined niacin and tryptophan intake against incident Parkinson’s disease without providing the kind of confirmed protective association that would strengthen the causal case.10,11 Observational designs of this type are in any event particularly vulnerable to reverse causation, because prodromal Parkinson’s disease alters diet, smell, appetite, and gastrointestinal function years before diagnosis. The fifth limitation is conceptual: “NAD+ deficiency” is not a single, cleanly measured, universally agreed entity in Parkinson’s disease. Different studies measure NAD+ in different tissues (brain, cerebrospinal fluid, blood, skeletal muscle) using different techniques, and these compartments do not move in lockstep. The finding of lower NAD+ or lower NAD+-synthesizing enzymes in some Parkinson’s tissues is real and reproducible in places, but whether it is a primary driver of neurodegeneration, a downstream consequence of mitochondrial failure, or both at once is not resolved.4,6 A therapy premised on correcting a deficiency needs a clear picture of what deficiency it is correcting and where. Until the NOPARK results and comparable trials are published and, ideally, independently replicated, the responsible bottom line is that NAD+ precursors remain an unproven, investigational approach in Parkinson’s disease, however biologically attractive the rationale.3

Source: dosagepeptide.com ↗

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

AOD-9604’s clinical record lives almost entirely in obesity, and understanding it is the fairest way to gauge whether any of the preclinical antilipogenic promise translated to people. The short version: it was tested seriously, in humans, at scale, and it did not deliver on its primary endpoint — and none of the human work measured lipogenesis at all. Across development, AOD-9604 was studied in roughly six human clinical trials enrolling more than 900 participants in total, a tally that derives from the sponsor’s development-program summary rather than a single publication.10 The centerpiece early study, a 12-week Phase 2 evaluation in obese adults (METAOD005) using once-daily oral dosing across several dose arms, was encouraging: the 1 mg arm reportedly lost more weight than placebo, and the results generated optimistic press.10 But the pivotal, longer, more rigorously controlled 24-week study (METAOD006) — a randomized, double-blind, placebo-controlled, multicenter trial that is the single published RCT on the compound — found that the weight-loss difference between AOD-9604 and placebo did not reach statistical significance at the primary endpoint, especially against a background of intensive diet and exercise.10 Development as an obesity drug was terminated in 2007. Two points matter for the antilipogenic question. First, every human study used weight and body-composition endpoints, plus safety and pharmacokinetic measures. None used the tools that actually quantify de novo lipogenesis in people — stable-isotope tracers (for example, deuterated water incorporation into palmitate), adipose or hepatic lipogenic-gene expression, or measured lipogenic flux. So even the human trials that exist are silent on whether AOD-9604 reduces fat synthesis; they measured the downstream outcome (weight), not the mechanism (lipogenesis), and the downstream outcome was not robustly positive. Second, the reassuring endocrine profile held up: the compound was reported not to raise IGF-1 and not to impair glucose tolerance, consistent with the “GH activity modulation” design.1 Trials ~6 studies, >900 participants total10 Pivotal design 24-week randomized, double-blind, placebo-controlled, multicenter (METAOD006); oral10 Primary endpoint Weight difference vs placebo did NOT reach statistical significance10 Lipogenesis measured? No — no DNL tracer, lipogenic-gene, or flux endpoints in any human study Endocrine profile No reported IGF-1 rise; no impaired glucose tolerance1 Outcome Obesity development halted in 200710 The honest reading is stark: the compound’s best-evidenced outcome (fat loss in obesity) was itself not robustly demonstrated in humans, and its proposed mechanism (reduced lipogenesis) was never measured in humans at all. Extrapolating from “inhibited ACC in rat fat pads” to “reduces lipogenesis in people” is a leap across species, tissues, and measurement methods, with no human data on the far side. For a measured look at how the clinical results are often characterized, see the site’s summary of what clinical trials indicate about the fat-burning potential of AOD-9604.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step Frequency: one subcutaneous injection each day. The 4 mg/day dose and the 1–4–8 mg dose-ranging arms are real Phase 2 parameters[3][4], but Phase 2 results are early-stage and proven efficacy should not be assumed.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →